BR112016029460A2 - métodos para tratar artrite reumatoide - Google Patents

métodos para tratar artrite reumatoide

Info

Publication number
BR112016029460A2
BR112016029460A2 BR112016029460A BR112016029460A BR112016029460A2 BR 112016029460 A2 BR112016029460 A2 BR 112016029460A2 BR 112016029460 A BR112016029460 A BR 112016029460A BR 112016029460 A BR112016029460 A BR 112016029460A BR 112016029460 A2 BR112016029460 A2 BR 112016029460A2
Authority
BR
Brazil
Prior art keywords
methods
rheumatoid arthritis
treat rheumatoid
treating
treat
Prior art date
Application number
BR112016029460A
Other languages
English (en)
Inventor
Masteller Emma
Xiang Hong
Zanghi James
Hambleton Julie
Sikorski Robert
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201462015710P priority Critical
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Priority to PCT/US2015/036419 priority patent/WO2015200089A1/en
Publication of BR112016029460A2 publication Critical patent/BR112016029460A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/825Arthritis

Abstract

são fornecidos métodos para tratar condições com anticorpos que se ligam ao receptor do fator 1 estimulador de colônias (csf1r). esses métodos incluem, mas não se limitam a, métodos para tratar artrite reumatoide.
BR112016029460A 2014-06-23 2015-06-18 métodos para tratar artrite reumatoide BR112016029460A2 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201462015710P true 2014-06-23 2014-06-23
PCT/US2015/036419 WO2015200089A1 (en) 2014-06-23 2015-06-18 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)

Publications (1)

Publication Number Publication Date
BR112016029460A2 true BR112016029460A2 (pt) 2017-10-24

Family

ID=53674259

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016029460A BR112016029460A2 (pt) 2014-06-23 2015-06-18 métodos para tratar artrite reumatoide

Country Status (13)

Country Link
US (2) US10975153B2 (pt)
EP (1) EP3157957A1 (pt)
JP (2) JP6964410B2 (pt)
KR (1) KR20170016501A (pt)
CN (2) CN113350501A (pt)
AU (1) AU2015280362B2 (pt)
BR (1) BR112016029460A2 (pt)
CA (1) CA2951156A1 (pt)
EA (1) EA037561B1 (pt)
IL (1) IL249393A (pt)
MX (1) MX2016016664A (pt)
SG (2) SG10201811475YA (pt)
WO (1) WO2015200089A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2018195283A1 (en) * 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
CN108948199B (zh) * 2018-07-18 2019-06-21 博奥信生物技术(南京)有限公司 抗人csf-1r单克隆抗体及其用途
CN109053887B (zh) * 2018-07-18 2019-07-23 博奥信生物技术(南京)有限公司 一种抗人csf-1r单克隆抗体及用途
US20210317461A1 (en) 2018-08-09 2021-10-14 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0382781B1 (en) 1987-10-23 1993-09-29 Genetics Institute, Inc. Composition for treating cancers characterized by over-expression of the c-fms proto-oncogene
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993025687A1 (en) 1992-06-09 1993-12-23 Chiron Corporation Crystallization of m-csf
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
JPH10218791A (ja) 1997-01-31 1998-08-18 Toagosei Co Ltd 慢性関節リウマチ治療薬
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
WO1999029345A1 (en) 1997-12-05 1999-06-17 La Jolla Institute For Experimental Medicine Inhibition of tumor growth by macrophage intervention
CA2348292A1 (en) 1998-10-30 2000-05-11 Takeda Chemical Industries, Ltd. Betacellulin protein-containing preparation
PL200134B1 (pl) 1999-05-07 2008-12-31 Genentech Inc Zastosowanie przeciwciała anty-CD20
DE50002293D1 (de) 1999-10-28 2003-06-26 Hofbauer Reinhold Verwendung von csf-1-inhibitoren
AU1759501A (en) 1999-11-08 2001-06-06 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Method of treating a viral infection using antagonists of macrophage colony stimulating factor
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
US6773895B2 (en) 2000-09-01 2004-08-10 Boehringer Ingelheim Pharma Kg Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
US7247618B2 (en) 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
EP1423428B2 (en) 2001-06-20 2012-11-14 Fibron Ltd. Antibodies that block fgfr3 activation, methods of screening for and uses thereof
JP4727992B2 (ja) 2002-11-15 2011-07-20 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド 癌転移および癌転移に伴なう骨量減少を予防および処置するための方法
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
EP2330201B1 (en) 2003-10-22 2017-04-05 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
GB0325836D0 (en) 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
WO2005070447A2 (en) 2004-01-21 2005-08-04 Chiron Corporation M-csf muteins and uses thereof
CA2565974A1 (en) 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
AU2005267062C1 (en) 2004-07-22 2013-01-17 Five Prime Therapeutics, Inc. Compositions and methods of use for MGD-CSF in disease treatment
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
DK1841874T3 (da) 2005-01-27 2010-05-17 Five Prime Therapeutics Inc Leadersekvenser til at lede secernering af polypeptider og fremgangsmåder til fremstilling heraf
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
AU2006320858A1 (en) 2005-11-10 2007-06-07 Receptor Biologix, Inc. Methods for production of receptor and ligand isoforms
WO2007075933A2 (en) 2005-12-21 2007-07-05 Cell Signaling Technology, Inc. Translocation and mutant csf1r kinase in human leukemia
AU2006342119B8 (en) 2005-12-22 2013-05-09 Novartis Ag Soluble human M-CSF receptor and uses thereof
AU2007205048B2 (en) 2006-01-05 2013-07-04 Novartis Ag Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
AU2007248493B2 (en) 2006-05-04 2010-09-30 The Rockefeller University HCV coreceptor and methods of use thereof
US7833789B2 (en) 2006-08-01 2010-11-16 Fondazione Centro San Raffaele Del Monte Tabor Monocyte cell
US20100266528A1 (en) 2006-11-17 2010-10-21 Biogen Idec Ma Inc. Systemic Administration of Colony Stimulating Factors to Treat Amyloid Associated Disorders
DE602008004296D1 (de) 2007-02-14 2011-02-17 Vaccinex Inc Humanisierte anti-cd100-antikörper
WO2008124858A2 (en) 2007-04-11 2008-10-23 F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. Targeted receptor
US20100298217A1 (en) 2007-05-30 2010-11-25 Evan Richard Stanley Csf-1r mutants
PL2188313T3 (pl) 2007-08-21 2018-04-30 Amgen, Inc. Białka wiążące ludzki antygen c-fms
US7981415B2 (en) 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
US20090148883A1 (en) 2007-10-31 2009-06-11 Manthey Carl L Biomarker for assessing response to fms treatment
US20110262425A1 (en) 2007-12-12 2011-10-27 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
AU2009224955B2 (en) 2008-03-14 2012-08-09 Transgene S.A. Antibody against the CSF-1 R
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
WO2010062399A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
EP2949670B1 (en) 2009-12-10 2019-02-27 F. Hoffmann-La Roche AG Antibodies binding preferentially human csf1r extracellular domain 4 and their use
CA2789071C (en) 2010-03-05 2018-03-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
MX355418B (es) * 2010-05-04 2018-04-18 Five Prime Therapeutics Inc Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
AR084234A1 (es) 2010-12-13 2013-05-02 Novartis Ag Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17)
CA2852800A1 (en) 2011-10-21 2013-04-25 Inserm (Institut National De La Sante Et De La Recherche Medicale) A m-dc8+ monocyte depleting agent for the prevention or the treatment of a condition associated with a chronic hyperactivation of the immune system
EP2768862A2 (en) 2011-10-21 2014-08-27 Transgene SA Modulation of macrophage activation
BR112014028013A2 (pt) * 2012-05-11 2018-02-27 Five Prime Therapeutics Inc métodos para tratar uma condição associada com artrite reumatoide, artrite reumatoide, lesões de pele, nefrite lúpica, lúpus, uma condição inflamatória, distúrbio de cd16+, método para reduzir o número de monócitos cd16+, métodos para desacelerar a progressão de uma condição renal,de formação de panos e de perda óssea
TW201919691A (zh) 2012-08-31 2019-06-01 美商戊瑞治療有限公司 用結合群落刺激因子1受體(csf1r)之抗體治療病狀之方法
WO2016069727A1 (en) * 2014-10-29 2016-05-06 Five Prime Therapeutics, Inc. Combination therapy for cancer

Also Published As

Publication number Publication date
SG11201610672YA (en) 2017-01-27
US10975153B2 (en) 2021-04-13
EA037561B1 (ru) 2021-04-14
CA2951156A1 (en) 2015-12-30
EP3157957A1 (en) 2017-04-26
JP6964410B2 (ja) 2021-11-10
EA201692482A1 (ru) 2017-05-31
CN106795222A (zh) 2017-05-31
US20210317219A1 (en) 2021-10-14
CN113350501A (zh) 2021-09-07
IL249393D0 (en) 2017-02-28
SG10201811475YA (en) 2019-02-27
KR20170016501A (ko) 2017-02-13
AU2015280362A1 (en) 2016-12-22
US20170152320A1 (en) 2017-06-01
AU2015280362B2 (en) 2021-03-04
IL249393A (en) 2022-02-01
JP2020169179A (ja) 2020-10-15
JP2017520562A (ja) 2017-07-27
WO2015200089A1 (en) 2015-12-30
MX2016016664A (es) 2017-03-20

Similar Documents

Publication Publication Date Title
EA202092435A2 (ru) Моноклональные антитела против bcma
MX2018015592A (es) Anticuerpos inhibidores de puntos de control biespecificos.
ECSP17070399A (es) Anticuerpos contra icos
ECSP17044494A (es) Receptores de antígenos quiméricos de bcma
CL2016001871A1 (es) Anticuerpos humanos para pd-1
CY1118168T1 (el) Διπλα ειδικα αντισωματα εναντι cd3εψιλον και bcma
BR112017007170A2 (pt) anticorpos anti-ox40 humanizados e suas utilizações
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201790926A1 (ru) Комбинированное лечение злокачественного новообразования
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
BR112016029460A2 (pt) métodos para tratar artrite reumatoide
MX369645B (es) Anticuerpos multiespecificos.
CL2016002157A1 (es) Anticuerpos anti-cd38 para el tratamiento de leucemia linfoide aguda
EA201791208A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
MX2017008218A (es) Anticuerpos anti-csf1r para tratar pvns.
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
EA201790643A1 (ru) Способ и устройство для непрерывного нанесения нанослоистых металлических покрытий
PH12017502237A1 (en) Nuclear receptor modulators
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
TR201819099T4 (tr) Besleme malzemenin işlenmesi için düzenek ve yöntem.
GB2535937B (en) Arginase I for treating rheumatoid arthritis
TW201713333A (en) Methods of treating a neurodegenerative disease
FR3021455B1 (fr) Procede d'aplanissement d'evidements remplis de cuivre
CL2019001381A1 (es) Método para el tratamiento de glomeruloesclerosis segmentaria focal.
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]